MARKET NEWS

Acer Therapeutics Submits NDA for EDSIVO; Requests Priority Review
TESARO Announces $18-Million Milestone Payments
Athenex Announces FDA Allowance of Investigational New Drug Application
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate From Ionis Pharmaceuticals
Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program
Enable Injections’ First Closing of Series B Round to Include New Investor

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Founded in 1977, JRF Global is one of the oldest (40+ years) and most respected non-clinical Contract Research Organization in Asia. JRF’s capabilities spanning from Discovery to Development phase provides integrated services to both innovator and generic pharma companies. JRF Global’s top management is committed and actively involved in the establishment, management and monitoring of quality systems. This is achieved by documenting quality policies and objectives and ensuring that both are understood and implemented by all scientists’ at all the levels. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Verona Pharma Completes Enrollment in Phase 2 Clinical Trial

Verona Pharma Completes Enrollment in Phase 2 Clinical Trial

Verona Pharma plc recently announced it has enrolled the last patient in its Phase 2 clinical trial evaluating the effect of nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic/long-acting beta2-agonists (LAMA/LABA) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe COPD.

Sanofi & Denali Therapeutics to Develop Multiple Molecules; 5 Million Upfront

Sanofi & Denali Therapeutics to Develop Multiple Molecules; $125 Million Upfront

Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases.

Nemera’s e-Novelia® Ophthalmic Add-On Wins “Excellence in Pharma: Drug Delivery Devices” Award

Nemera’s e-Novelia® Ophthalmic Add-On Wins “Excellence in Pharma: Drug Delivery Devices” Award

A team of industry experts awarded Nemera’s electronic add-on for ophthalmic droppers with a prestigious CPhI Award for Best Drug Delivery Device in its category.

Alcami Helps Medicines Development for Global Health Secure FDA Approval

Alcami Helps Medicines Development for Global Health Secure FDA Approval

Alcami Corporation recently announced its collaboration with Medicines Development for Global Health (MDGH), a not-for-profit Australian biopharmaceutical company dedicated to the development of affordable medicines and vaccines for neglected diseases prevalent in low and middle-income countries.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 14 – Prefilled Syringes
November 21 – Analytical Instruments